Evaluation of DNA flow cytometry as a sc
โ
Ralph W. Devere White; Arline D. Deltch
๐
Article
๐
1992
๐
John Wiley and Sons
๐
English
โ 531 KB
At this present time, we feel that there is no role for DNA flow cytometry (FCM), or indeed DNA studies by any other method, to be used as a screening procedure for patients with no prior history of bladder cancer due to the high false-positive rate found when monitoring exfoliated urothelial cells.